IL-17 inhibitors work by binding to IL-17 cytokines, preventing them from interacting with their receptors on the surface of various cell types, such as epithelial cells and fibroblasts. This inhibits the downstream signaling pathways that lead to inflammation. The result is a reduction in the recruitment of immune cells like neutrophils and a decrease in the production of other inflammatory cytokines and chemokines.